

# NIH funding opportunities

08 May 2024 (#13)



**Confirm your intent to apply *ASAP*, but not later than *60 days* before the submission date.**



See all Important Notices, Parent Announcements and Notice of Special Interest below

**Plan your application. Before starting your application attend**

- 1) *Generic Grant Writing Workshop and then the*
- 2) *NIH Grant Writing Workshop*

**To prepare an application can take *4-18 months*.**

**From submission to receiving a Notice of Award can take *10 months***

## Important Notices

**[NOT-OD-24-105](#) “NIH Grants Process: A Brief Walk-Through for Beginners” – Registration Open for May 15, 2024 Webinar.** Are you new to working with the NIH grants process? If so, make plans to join your peers as the NIH walks through essential aspects of applying for funding. This event offers participants an opportunity to gain insight into the NIH’s organizational structure and how it funds research, resources to help find the right fit for your research including NIH Notices of Funding Opportunities (NOFOs), an overview of the grants process and peer review, NIH and applicant institution roles/responsibilities, and where to access help along the way.

- Date: Wednesday, May 15, 2024
- Time: 1:00 – 2:30 p.m. ET
- [Registration Required](#)

**[NOT-CA-24-045](#) Notice of Preapplication Webinar for NOSI [NOT-CA-24-033](#): Telehealth Research in Cancer Care.** The pre-application webinar will be held on **Monday, May 13, 2024**, from 1:00 pm - 1:30 pm ET. **Registration for the webinar is required.** Register at <https://healthcaresdelivery.cancer.gov/media/NOT-CA-24-033.html>.

**[NOT-NS-24-079](#) NINDS Policy for applications requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) on NIH Parent R01 Notices of Funding Opportunities.** Effective immediately, NINDS will establish a more stringent payline for all grants applications requesting \$500,000 or more in direct costs in any year.

**[NOT-OD-24-109](#) Notice of Fiscal Policies in Effect for FY 2024.** This Notice provides guidance about the NIH Fiscal Operations for Fiscal Year 2024.

**[NOT-OD-24-110](#) Notice of Legislative Mandates in Effect for FY 2024.** The Further Consolidated Appropriations Act, 2024 ([Public Law No: 118-47](#)), signed into law on March 23, 2024, provides funding to NIH for the Fiscal Year ending September 30, 2024. The intent of this notice is to provide current requirements outlined in the following statutory provision that limits or conditions the use of funds on NIH grant, cooperative agreement, and contract awards for FY 2024.

[NOT-OD-24-115](#) **Publication of the Revised NIH Grants Policy Statement (Rev. April 2024) for Fiscal Year 2024.** The NIHGPS provides both up-to-date policy guidance that serves as NIH standard terms and conditions of award for all NIH grants and cooperative agreements, and extensive guidance to those who are interested in pursuing NIH grants.

[NOT-EY-24-006](#) **Standardized Ocular Imaging Expectations for Clinical and Nonclinical Research Funded by NEI.** The purpose of this notice is to inform potential applicants that the National Eye Institute (NEI) strongly encourages the use of common formats for files and metadata standards when incorporating ocular imaging in applications. This applies to both Clinical and Nonclinical research applications submitted in response to Notice of Funding Opportunities (NOFO) when NEI is the issuing or participating organization.

[NOT-OD-24-117](#) **Notice of Information: Research Opportunities Centering the Health of Women Across the HIV Research Continuum.** The NIH Office of Research on Women's Health (ORWH) and Office of AIDS Research (OAR), in partnership with our Institute, Center, and Office (ICO) partners are issuing this Notice of Information to provide a centralized list of opportunities in HIV research and training grant applications that explicitly and intersectionally center the health needs of cisgender women and girls, and gender-diverse people. Despite tremendous scientific advances that have translated to substantial progress in confronting the HIV epidemic, women—particularly women of color, young women and girls, and transgender women—and gender-diverse individuals remain disproportionately affected by HIV. An intersectional, equity-informed, data-driven approach is essential to advance HIV research and clinical care for all women with or impacted by HIV across their lifespan and to end the HIV pandemic ([Barr et al, 2024](#)).

## Parent Announcements

[NOT-OD-24-099](#) **Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities.** Current Key Dates **Modified Expiration Date: January 8, 2025**

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notice of Special Interest (NOSI)

[NOT-CA-24-039](#) **Administrative Supplements for NCI Center for Global Health Research Programs.** The National Cancer Institute (NCI) Center for Global Health (CGH) seeks to support impactful research that leverages scientific opportunities afforded by global collaboration. The purpose of this Notice of Special Interest (NOSI) is to highlight CGH's interest in supporting studies aimed at fostering collaborations between researchers who are part of CGH's funded research networks or partnering with researchers on CGH's networks. This supplemental opportunity will support current awardees of CGH-led or co-led networks. **Due date** 22 May 2024.

[NOT-DA-25-030](#) **Exploring the Effects of Endocannabinoids and Exogenous Cannabinoids on Brain Development.** The purpose of this NOSI is to encourage investigators to submit grant applications to the National Institute on Drug Abuse (NIDA) to investigate the roles of endocannabinoids and the effects of cannabinoid exposure in the developing brain, from fetal development through young adulthood in humans and animal models.

[NOT-OD-24-096](#) **Promoting Data Reuse for Health Research.** This NOSI solicits competitive revision applications that focus on data reuse and secondary data analysis in NIH-funded data repositories and knowledgebases to advance scientific inquiry and address health research questions. Office of Data Science Strategy ([ODSS](#)) intends to commit \$275,000 direct costs per award which can be used for up to two years.

**[NOT-TW-24-005](#) Catalyzing Research and Training on the Impact of HIV on the Health Across the Lifespan of Women Living with HIV Through Administrative Supplements to Existing Fogarty International Center’s HIV Programs.** The Fogarty International Center (FIC), supported with funds from the Office of AIDS Research (OAR) at the National Institutes of Health (NIH), invites supplement applications from currently funded HIV/AIDS **research** or **research training grants** to initiate research on the emerging need to address critical gaps in understanding the impact of HIV on the health of Women Living With HIV (WLWH) and to get a better understanding of the consequences of the intersectionality of HIV infection and women’s health at a more psychological, biological and physiological level. FIC will provide up to \$100,000 Total costs per supplement. **Due before June 20, 2024.**

## Notice of Funding Opportunity (NOFO)

**1. [RFA-HD-25-009](#) Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research (R21 - Clinical Trial Not Allowed).** The purpose of this Notice of Funding Opportunity (NOFO) is to utilize archived HIV/AIDS data and biospecimen collections to generate new research questions and findings related to epidemiology, pathogenesis, treatment, prevention, clinical manifestations, and HIV-associated co-infections in maternal, pediatric, and adolescent populations.

**Due date:** July 24, 2024. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Letter of Intent: 30 days prior to the application due date.

**Budget:** The following NIH components intend to commit the following amounts in FY 2025. NICHD, \$900,000, 3-4 awards. NIMH, \$200,000, 1 award. Direct costs are limited to \$275,000 over a two-year period, with no more than \$200,000 in direct costs in any year.

**2. [RFA-AI-24-010](#) Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical Trial Not Allowed).** The purpose of this notice of funding opportunity (NOFO) is to support the evaluation of early-stage diagnostics and novel diagnostic strategies for Tuberculosis (TB) in the context of existing clinical algorithms in TB endemic countries. Evaluation studies should: 1) perform proof-of principle studies of novel diagnostic tests and strategies for TB, including among people living with HIV (PLWH) and 2) provide feedback to diagnostic developers and policy makers on the performance of the technologies and most effective strategies for use of the diagnostic technologies in an endemic setting.

**Due date:** June 28, 2024. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

**Budget:** NIAID intends to commit \$5,500,000 in FY 2025 to fund 1-2 awards. Application budgets are not limited but are not expected to exceed \$3,500,000 in direct costs per year and need to reflect the actual needs of the proposed project. The project period must be 5 years.

**3. [PAR-24-216](#) Minor Use Minor Species Development of Drugs (R01).** This NOFO issued by Center for Veterinary Medicine (CVM) of Food and Drug Administration ([FDA](#)) solicits Research Project (R01) grant applications from institutions or organizations that propose to develop or support the development of designated new animal drugs intended for minor uses in major species or for use in minor species (MUMS).

**Due date:** July 26, 2024; January 31, 2025; July 25, 2025. All applications are due by 11:59 PM Eastern Time.

**Budget:** The nature and scope of the proposed research will vary from application to application. Application budgets need to reflect the actual needs of the proposed project and should not exceed the following in total costs. YR 01: \$250,000. The maximum project period is 3 years (long-term toxicological study)

<p style="text-align: center;"><b>Faculty of Medicine and Health Sciences Research &amp; Internationalisation Development &amp; Support (RIDS) &amp; Grants Management Office (GMO)</b> 009 K<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.</p>	<p style="text-align: center;"><b>Stellenbosch Campus Division for Research Development (DRD)</b> 2041 Krotoa Building, Ryneveld Street</p>
<p><b>Enquiries:</b> <a href="mailto:cdevries@sun.ac.za">cdevries@sun.ac.za</a> / <a href="mailto:fmhsgmo@sun.ac.za">fmhsgmo@sun.ac.za</a></p>	<p><b>Enquiries:</b> <a href="mailto:research@sun.ac.za">research@sun.ac.za</a></p>
<p style="text-align: center;"><b>Add “Interest in NIH opportunity” in the subject line. Add the notice number in the text of the email.</b></p>	